Pharmacological ErbB inhibitors induce tumor cell apoptosis by blocking these aberrantly activated signaling pathways; however, ErbBs are not known regulators of neutrophil apoptosis, and their role in neutrophils and other immune cells is sparsely studied. Here, EGFR is linked to neoplasm.